全球细支气管炎药物市场 – 行业趋势和 2029 年预测

市场分析和规模

细支气管炎是婴儿下呼吸道最常见的疾病。每年有 21% 的北美婴儿患有下呼吸​​道疾病，而大多数婴幼儿只会患上轻微的细支气管炎。另一方面，支气管炎在出生后第一年影响多达 3% 的儿童。呼吸道合胞病毒 (RSV) 是 70% 细支气管炎病例的罪魁祸首，冬季的病例占 80% 至 100%。其余病例大多由副流感病毒、腺病毒和流感引起。

Data Bridge Market Research 分析称，2021 年细支气管炎药物市场价值为 5862 万美元，预计到 2029 年将达到 8337 万美元，在 2022 年至 2029 年的预测期内复合年增长率为 4.50%。Data Bridge Market Research 团队策划的市场报告包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。

报告范围和市场细分

Market Definition

Bronchiolitis is a recurring lung illness that affects new-borns and small children. It causes inflammation and obstruction in the lungs' tiny airways (bronchioles). It can make you wheeze, cough and have trouble breathing. It occurs when the bronchioles, or small breathing tubes in the lungs, get inflamed. As a result of the mucus clogging the tubes, there isn't enough room for air to get in and out of the lungs. The respiratory syncytial virus (RSV), influenza (flu) viruses and rhinovirus are the most common causes of bronchiolitis.

Bronchiolitis Drugs Market Dynamics

Drivers

• Rise in the prevalence of respiratory syncytial virus (RSV) infection

The surging prevalence of respiratory syncytial virus (RSV) infection is a major factor driving the bronchiolitis drugs market's growth rate. According to the Centers for Disease Control and Prevention (CDC), respiratory syncytial virus (RSV) causes the hospitalization of approximately 1,32,000-172,000 children under the age of five and the death of approximately 14,000 adults over the age of 65 in the United States alone each year. Developing countries account for nearly all RSV-related mortality in children under the age of five. Because respiratory syncytial virus (RSV) infections have clinical signs that are similar to those of other respiratory diseases, there is a rising demand for rapid, specific, and sensitive diagnostic procedures.

• High prevalence rate of smoking

The rise in prevalence rate of smoking will act as a major driver that will result in the expansion of the growth rate of the market. Smoking is one of the causative factor which increases the risk of viral bronchiolitis by raising breathing problems and hence will further cushion the growth rate of bronchiolitis drugs market.

Furthermore, rising initiatives by public and private organizations to spread awareness and rising healthcare expenditure will expand the bronchiolitis drugs market. Additionally, changing lifestyle of people and increasing number of cases of heart diseases and chronic lung disorders will result in the expansion of bronchiolitis drugs market. Along with this, rising incidences of respiratory diseases and increasing number of geriatric population will enhance the growth rate of the market.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the bronchiolitis drugs market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the bronchiolitis drugs market growth during the forecast period.

Restraints/Challenges

On the other hand, expiration of patented drugs and the introduction of generic version of drugs will obstruct the growth rate of market. The lack of healthcare infrastructure in developing economies and high cost associated with drugs will challenge the bronchiolitis drugs market. Additionally, side effects linked with bronchiolitis drugs will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This bronchiolitis drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the bronchiolitis drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

The respiratory syncytial virus causes the majority of viral bronchiolitis cases (RSV). Every autumn and winter, viral outbreaks mostly affect children under the age of two, with infants under the age of six months having the highest risk of serious disease. Bronchitis affects 11 to 15% of new-borns before they become one year old, and hospitalizes roughly 1 in 200 children under the age of two.

Bronchiolitis drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Bronchiolitis Drugs Market

Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in a number of nations had imposed nationwide lockdowns in order to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The lower respiratory tract infection treatment market was hampered by the supply chain slowness. On the bright side, the bronchiolitis drugs market is likely to improve as respective government bodies lifted the enforced lockdown restrictions. Various sectors are anticipated to rebound quickly post COVID-19 pandemic due to the wide number of applications they serve. As a result, the market is projected to stabilize in the future.

Recent Development

• In September 2021, Pfizer had announced the start of phase 3 clinical trials in adults for investigational vaccine named RENOIR against respiratory syncytial virus (RSV). The RSVpreF Phase 3 RENOIR trial is a global, randomised, double-blind, placebo-controlled investigation with a target enrollment of 30,000 people aged 60 and up.

Global Bronchiolitis Drugs Market Scope

The bronchiolitis drugs market is segmented on the basis of type, treatment, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Medication
• Antiviral drugs
• Aerosolized ribavirin
• Bronchodilators
• Corticosteroids
• Oxygen Therapy
• Intravenous Fluids
• Others

Type

• Viral Bronchiolitis
• Bronchiolitis Obliterans
• Others

Dosage Form

• Injection
• Tablets
• Others

Route of Administration

• Inhalational
• Parenteral
• Oral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Pipeline Analysis

MV130 (Bactek) 正在由 Inmunotek 开发，用于治疗细支气管炎。除了引发针对制剂中存在的细菌的特异性 T 细胞免疫之外，MV130 还表现出对无关流感抗原的增强的 T 细胞反应。TLR 和 NLR 信号通路在树突状细胞上被触发，导致释放经过训练的免疫标记物。

细支气管炎药物市场区域分析/见解

对细支气管炎药物市场进行了分析，并按国家、类型、治疗、剂型、给药途径、最终用户和分销渠道提供了市场规模见解和趋势。

细支气管炎药物市场报告涵盖的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区（APAC）的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲（MEA）的其他地区、南美洲的巴西、阿根廷和南美洲其他地区

北美在市场份额和市场收入方面占据细支气管炎药物市场的主导地位，并将在预测期内继续保持主导地位。这是由于主要关键参与者的存在，而不断增长的医疗保健支出将进一步推动该地区市场的增长率。

由于亚太地区炎症性呼吸道疾病的患病率激增，预计该地区在 2022-2029 年的预测期内将实现增长。此外，医疗保健基础设施的发展将进一步推动该地区市场的增长率。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和细支气管炎药物市场份额分析

细支气管炎药物市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对细支气管炎药物市场的关注有关。

细支气管炎药物市场的一些主要参与者包括：

• 辉瑞公司（美国）
• 葛兰素史克公司 (英国)
• 诺华公司（瑞士）
• Mylan NV（美国）
• Teva Pharmaceutical Industries Ltd.（以色列）
• 赛诺菲（法国）
• 勃林格殷格翰国际有限公司（德国）
• 阿斯利康（英国）
• 强生私人有限公司（美国）
• 默克公司（美国）
• F. Hoffmann-La Roche Ltd.（瑞士）
• 百时美施贵宝公司 (美国)
• 礼来公司 (美国)
• 艾尔建（爱尔兰）
• 雅培（美国）
• LEO Pharma A/S（丹麦）
• 太阳制药工业有限公司 (印度)
• Aurobindo Pharma（印度）
• 鲁冰花（印度）
• Hikma Pharmaceuticals PLC（英国）
• Amneal Pharmaceuticals LLC.（美国）
• Zydus Cadila（印度）
• Akorn 公司（美国） 

SKU-56309